
Neogen Corporation NEOG
$ 9.93
3.82%
Quarterly report 2025-Q4
added 01-08-2026
Neogen Corporation General and Administrative Expenses 2011-2026 | NEOG
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Neogen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 218 M | 200 M | 201 M | 82.7 M | 51.2 M | 44.3 M | 40.8 M | 38.3 M | 34.2 M | 29.2 M | 25.2 M | 24.4 M | 20.2 M | 17 M | 15.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 218 M | 15.1 M | 69.5 M |
Quarterly General and Administrative Expenses Neogen Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 65.2 M | 60.9 M | - | 55.8 M | 57.8 M | 51.7 M | - | 52.1 M | 51.7 M | 45.1 M | - | 46.4 M | 77 M | 27.9 M | 105 M | 25 M | 22.6 M | 13.4 M | 36 M | 15.1 M | 12.2 M | 11 M | 12.2 M | 10.8 M | 11 M | 10.7 M | 11 M | 10.7 M | 10.1 M | 10.2 M | 10.1 M | 10.2 M | 10.5 M | 9.32 M | 10.5 M | 9.32 M | 8.28 M | 8.26 M | 8.28 M | 8.26 M | 6.79 M | 6.75 M | 6.79 M | 6.52 M | 6.09 M | 6.01 M | 6.09 M | 6.01 M | 6.28 M | 5.54 M | 6.28 M | 5.54 M | 4.9 M | 4.48 M | 4.9 M | 4.48 M | 4.17 M | 4.01 M | 4.17 M | 4.01 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 105 M | 4.01 M | 19.7 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
1.62 B | $ 113.25 | -1.38 % | $ 34.4 B | ||
|
CareDx, Inc
CDNA
|
108 M | $ 17.42 | -2.24 % | $ 928 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M | ||
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
490 M | $ 16.35 | 0.28 % | $ 172 M | ||
|
Co-Diagnostics
CODX
|
9.06 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Danaher Corporation
DHR
|
8.24 B | $ 189.05 | -1.58 % | $ 135 B | ||
|
Aspira Women's Health
AWH
|
7.96 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | ||
|
DexCom
DXCM
|
1.29 B | $ 63.32 | 0.17 % | $ 24.7 B | ||
|
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
743 M | $ 166.89 | -0.79 % | $ 8.27 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | ||
|
Castle Biosciences
CSTL
|
200 M | $ 24.75 | 0.08 % | $ 687 M | ||
|
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | ||
|
Biodesix
BDSX
|
80.5 M | $ 14.37 | -6.48 % | $ 1.86 B | ||
|
Fulgent Genetics
FLGT
|
88.1 M | $ 15.98 | -2.68 % | $ 483 M | ||
|
Guardant Health
GH
|
211 M | $ 90.17 | 0.56 % | $ 11.3 B | ||
|
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B | ||
|
Anixa Biosciences
ANIX
|
6.63 M | $ 2.61 | 0.58 % | $ 84.7 K | ||
|
ICON Public Limited Company
ICLR
|
585 M | $ 107.87 | -1.6 % | $ 8.9 B | ||
|
Illumina
ILMN
|
1.09 B | $ 126.04 | -1.33 % | $ 20 B | ||
|
Biomerica
BMRA
|
2.98 M | $ 2.13 | -1.84 % | $ 4.89 M | ||
|
BioNano Genomics
BNGO
|
35.2 M | $ 1.15 | -0.43 % | $ 6.26 M | ||
|
Interpace Biosciences
IDXG
|
9.48 M | $ 1.98 | 0.51 % | $ 8.76 M | ||
|
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 271.93 | -0.96 % | $ 22.6 B | ||
|
Lantheus Holdings
LNTH
|
275 M | $ 76.19 | 0.4 % | $ 5.14 B | ||
|
Celcuity
CELC
|
27.2 M | $ 113.92 | -0.26 % | $ 5.33 B | ||
|
Medpace Holdings
MEDP
|
198 M | $ 501.47 | 1.1 % | $ 14.5 B | ||
|
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | ||
|
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | ||
|
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | ||
|
Myriad Genetics
MYGN
|
257 M | $ 4.64 | -0.54 % | $ 430 M | ||
|
NeoGenomics
NEO
|
273 M | $ 7.9 | -1.5 % | $ 1.01 B | ||
|
Exact Sciences Corporation
EXAS
|
889 M | - | - | $ 19.8 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.97 B | $ 198.9 | -0.08 % | $ 22.1 B | ||
|
National Research Corporation
NRC
|
54.8 M | $ 17.07 | -1.5 % | $ 382 M | ||
|
Natera
NTRA
|
589 M | $ 206.47 | 0.78 % | $ 20.3 B | ||
|
ENDRA Life Sciences
NDRA
|
3.72 M | $ 4.71 | -0.74 % | $ 3.71 M | ||
|
Pacific Biosciences of California
PACB
|
141 M | $ 1.42 | - | $ 426 M | ||
|
Koninklijke Philips N.V.
PHG
|
599 M | $ 26.78 | -1.58 % | $ 20 B | ||
|
Precipio
PRPO
|
9.45 M | $ 26.03 | 0.19 % | $ 41.8 M | ||
|
Personalis
PSNL
|
46.2 M | $ 6.03 | -8.36 % | $ 357 M | ||
|
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B |